Skip to main content
Fig. 6 | Journal of Nanobiotechnology

Fig. 6

From: Tumor microenvironment-responsive DNA-based nanomedicine triggers innate sensing for enhanced immunotherapy

Fig. 6

The dsDNA@DMONs induced PD-L1 expression in tumor cells. A RT-qPCR analysis of the gene expression of Pd-l1 in MC38, B16-F10, 4T1, Panc02, MDA-MB-231 and A375 cells treated with PBS, DMONs (Si: 6 μg/mL), dsDNA (2.4 μg/mL) or dsDNA@DMONs (Si: 6 μg/mL) for 24 h. B Western blot assays of PD-L1 in B16-F10 cells treated with PBS, DMONs (Si: 6 μg/mL), dsDNA (2.4 μg/mL) or dsDNA@DMONs (Si: 6 μg/mL) with or without H-151 (2 μM) for 24 h. GAPDH serves as a loading control. C Analysis of PD-L1 expression on tumor cells in tumor tissues using flow cytometry. Data are shown as mean ± SEM (n ≥ 3). P value was calculated by unpaired Student's t-test in A and C. (**p < 0.01; ***p < 0.001)

Back to article page